argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
argenx is listed on Euronext Brussels and on the NASDAQ; all with the ticker symbol ARGX.
We have a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in argenx or are evaluating argenx as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.
Q3 2017 Business update & Financial results
HY 2017 Financial results & Q2 Business update
Annual report 2016